Free Trial
NASDAQ:AVBP

ArriVent BioPharma Q4 2024 Earnings Report

ArriVent BioPharma logo
$18.92 -0.29 (-1.51%)
As of 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ArriVent BioPharma EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.78
Beat/Miss
Beat by +$0.18
One Year Ago EPS
N/A

ArriVent BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ArriVent BioPharma Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 3, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

ArriVent BioPharma's Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled on Friday, November 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

ArriVent BioPharma Earnings Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
See More ArriVent BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ArriVent BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ArriVent BioPharma and other key companies, straight to your email.

About ArriVent BioPharma

ArriVent BioPharma (NASDAQ:AVBP) operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

View ArriVent BioPharma Profile

More Earnings Resources from MarketBeat